Rockefeller Capital Management’s VanEck Pharmaceutical ETF PPH Stock Holding History

Rockefeller Capital Management’s Portfolio PPH Stock Details PPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$65.1K	Buy	627 +352	+128%	+$37.5K	﹤0.01%	3128
2025 Q4	$28.4K	Sell	275 -4,630	-94%	-$450K	﹤0.01%	3350
2025 Q3	$443K	Buy	+4,905	New	+$430K	﹤0.01%	1829
2023 Q1	–	Sell	-1,300	Closed	-$101K	–	3398
2022 Q4	$101K	Hold	1,300	–	–	﹤0.01%	2020
2022 Q3	$87K	Hold	1,300	–	–	﹤0.01%	2065
2022 Q2	$99K	Buy	+1,300	New	+$101K	﹤0.01%	1954

Other funds holding PPH

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

BCIM

British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

ERSOT

Employees Retirement System of Texas Austin, Texas $11.4B AUM 21.6% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

JSAM

J. Safra Asset Management New York $1.86B AUM 22.95% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Avalon Trust Santa Fe, New Mexico $1.45B AUM 35.31% 1-Year Est. Return

Rockefeller Capital Management's PPH Position: Q1 2026 in Review

Rockefeller Capital Management increased its VanEck Pharmaceutical ETF (PPH) stake by 128% in Q1 2026, buying an estimated $37.5K and bringing the position to 627 shares worth $65.1K. The position accounts for ﹤0.01% of the portfolio, ranked #3128.

Rockefeller Capital Management first reported a position in PPH in Q2 2022 and has held it in 6 quarters since. The position peaked at $443K in Q3 2025. 147 funds tracked by Wall St. Rank hold PPH as of Q1 2026.

Rockefeller Capital Management held 627 shares of VanEck Pharmaceutical ETF worth $65.1K as of Q1 2026.
Rockefeller Capital Management bought 352 VanEck Pharmaceutical ETF shares in Q1 2026, an estimated $37.5K.
VanEck Pharmaceutical ETF made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q1 2026, its #3128 holding.
Rockefeller Capital Management first reported a position in VanEck Pharmaceutical ETF in Q2 2022 and has held it in 6 quarters since.
Rockefeller Capital Management's VanEck Pharmaceutical ETF position peaked at $443K in Q3 2025.
147 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q1 2026.

Based on Rockefeller Capital Management's 13F filing for Q1 2026, filed 14 May 2026.